Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone Trials

Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Siragusa, Sergio

Phoenix, NCT05924100 / 2021-001538-20: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Recruiting

Europe

Luspatercept Injection [Reblozyl]

Associazione Qol-one, Celgene BMS

Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia

12/24

12/29

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting

N/A

861

Europe

Observation

Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation

Idiopathic Thrombocytopenic Purpura

07/23

CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting

N/A

520

Europe

Quality of life questionnaires

Gruppo Italiano Malattie EMatologiche dell'Adulto

Multiple Myeloma

12/24

Junior, Alvaro Rabelo Alves

SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting

405

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26

Aslam, Shamaila A

MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting

1328

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Hypertriglyceridemia

07/26

10/26

SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Recruiting

300

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting

14013

Europe, Canada, US, RoW

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml

Novartis Pharmaceuticals

Primary Prevention of Atherosclerotic Cardiovascular Disease

04/29

Rinaldi, Gaetana

NCT05299580 / 2019-004760-21: "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Withdrawn

Europe

dabrafenib, Trametinib

Fondazione Melanoma Onlus, Novartis Farma S.p.A.

Melanoma

03/23

Chouhan, Jayshree

MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting

1328

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Hypertriglyceridemia

07/26

10/26

SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting

405

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Siragusa, Sergio

Phoenix, NCT05924100 / 2021-001538-20: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Recruiting

Europe

Luspatercept Injection [Reblozyl]

Associazione Qol-one, Celgene BMS

Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia

12/24

12/29

NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting

N/A

250

Europe

Ospedale di Circolo - Fondazione Macchi

SARS-CoV-2 Infection, Hematological Malignancies

10/22

ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting

N/A

861

Europe

Observation

Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation

Idiopathic Thrombocytopenic Purpura

07/23

CLARITY, NCT03190525: Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

Recruiting

N/A

520

Europe

Quality of life questionnaires

Gruppo Italiano Malattie EMatologiche dell'Adulto

Multiple Myeloma

12/24

Junior, Alvaro Rabelo Alves

SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting

405

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26

Aslam, Shamaila A

MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting

1328

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Hypertriglyceridemia

07/26

10/26

SHASTA-4, NCT06347016: Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Recruiting

300

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting

15374

Europe, Canada, Japan, US, RoW

Tirzepatide, LY3298176, Placebo

Eli Lilly and Company

Obesity, Overweight

10/27

VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting

14013

Europe, Canada, US, RoW

Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml

Novartis Pharmaceuticals

Primary Prevention of Atherosclerotic Cardiovascular Disease

04/29

Rinaldi, Gaetana

Withdrawn

Europe

dabrafenib, Trametinib

Fondazione Melanoma Onlus, Novartis Farma S.p.A.

Melanoma

03/23

Chouhan, Jayshree

MUIR-3, NCT06347133: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Recruiting

1328

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Hypertriglyceridemia

07/26

10/26

SHASTA-3, NCT06347003: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Recruiting

405

Europe, Canada, US, RoW

Plozasiran Injection, ARO-APOC3, Placebo

Arrowhead Pharmaceuticals

Severe Hypertriglyceridemia

07/26

10/26



	Diseases Companies Products Productz Mechanisms of Action Sites